Search Results

The Precision-Panc team at the University of Glasgow, with their Co-Sponsor, NHS Greater Glasgow & Clyde, announced the opening of the Phase II PRIMUS-006 study evaluating IMM-101, a broad-spectrum immunomodulatory agent containing heat-killed, whole cell Mycobacterium obuense, in combination with gemcitabine and pembrolizumab as first-line treatment in patients with metastatic pancreatic cancer.

Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today the presentation of new preclinical data at the 2024 congress of the European Society for Radiotherapy and Oncology (ESTRO).

Sampled1 today announced that the new genomics Sampled SMART Lab in Glasgow, UK, has initiated a project with Guardant Health, Inc., a leading precision oncology company, to manage blood samples for a large-scale lung cancer screening study.

Ono Pharmaceutical Co., Ltd. announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University aiming at validating novel therapeutic targets.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company’s upcoming new data from its HIV research and development programs to be presented at the 30th International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2022) in Glasgow, Scotland and virtually from October 23-26, 2022.

Orca Bio today announced new data will be presented during the 50th Annual Meeting of the EBMT in Glasgow, United Kingdom.

Sun Nuclear, a Mirion Medical company, will feature new and enhanced solutions for better Quality Management at the ESTRO Annual Meeting, May 3-6, in Glasgow, Scotland.